147: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 1

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation

Content provided by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

7d ago 22:01

MP3•Episode home

Send us a text

Blood is critical to global healthcare - vital for surgeries, trauma care, cancer treatment, and maternal health. Yet despite 120 million donations each year, a 100 million unit shortfall means nearly half the world’s needs go unmet.

One person who understands this crisis firsthand is Ari Gargir, CEO & Founder of RedC Biotech. After surviving a paragliding accident thanks to a life-saving transfusion, he set out to tackle the global blood shortage. His team is now developing universal, lab-grown red blood cells, eliminating the need for donors.

The added transitional phrase creates a smoother flow between the global problem and the personal story that follows.

Don’t miss these key insights from the full conversation:

The Global Crisis: Ari painted a vivid picture of the current state of blood supply. The problem is multifaceted - logistical issues, biological challenges, and socio-economic disparities in blood distribution exacerbate this shortage. Developed nations possess more blood resources, but low-income countries, where donation rates are staggeringly low, continually grapple with severe shortages.
Innovative Solutions: We learned about the groundbreaking technology Ari is developing at RedC Biotech. Using stem cells, they aim to create unlimited, universal, and donor-free red blood cells. This could be a game-changer, not only for transfusions but also for advanced therapeutic uses.
Impact on Healthcare: Ari is a strong advocate for O-negative blood, which can be used for up to 98% of people. But he’s especially focused on vulnerable patients - those with sickle cell disease, thalassemia, and complex immune conditions - who may need frequent transfusions.

Our conversation with Ari underscores the importance of innovation in biotechnology to address critical global healthcare issues. By creating a reliable, scalable supply of red blood cells, RedC Biotech holds the promise of saving countless lives and improving the quality of life for those dependent on regular blood transfusions.

Tune in to hear how Ari and RedC Biotech are shaping the future of transfusion medicine.

Connect with Ari Gargir:

LinkedIn: www.linkedin.com/in/ari-gargir-7107035

RedC Biotech: www.redcbiotech.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

149 episodes

#Science #Biology #Cell Culture Technology Innovation Aficionado #David Brühlmann: Biotech Entrepreneur #Bioprocess #Biotech #Cell Culture #Development #CMC #Manufacturing #Scale #Technology #Scientists #Innovation